Liver Cancer Drug Market Size To Reach $9.81 Billion By 2030

Liver Cancer Drug Market Growth & Trends

The global liver cancer drug market size is expected to reach USD 9.81 billion by 2030, registering a CAGR of 17.8% from 2024 to 2030, according to a new report by Grand View Research, Inc. The growth of liver cancer market is largely driven by factors such as availability of novel drugs, presence of strong pipeline, and rising public awareness. Widening base of liver cancer patients can be attributed to unhealthy lifestyles and growing geriatric population. This, in turn, is working in favor of the liver cancer therapeutics market. Therapeutic development in second-line setting for Nexavar-intolerant patients is estimated to have a major impact in the HCC space.

Liver cancer is the fifth most prevalent cancer worldwide and accounts for 9.0% of all cancer deaths. In 2012, 782,451 new cases of liver cancer were diagnosed, and 745,533 deaths were reported due to liver cancer. Primary liver cancer remains an important public health issue due to its extremely aggressive nature and poor survival rate. Hepatocellular carcinomas (HCCs) represents the majority (75–90%) of primary liver cancers. A noteworthy number of etiological factors of liver cancer, including hepatitis infection and cirrhosis, can be modified and present a strong prospect to reduce its incidence and mortality by preventive strategies such as lifestyle modification and hepatitis immunization.

 Request a free sample copy or view report summary: Liver Cancer Drug Market Report

Liver Cancer Drug Market Report Highlights

• The targeted therapy segment held the largest market revenue share of 53.0% in 2023 due to its precision in targeting specific molecules or pathways involved in the growth and spread of cancer cells.

• Hepatocellular Carcinoma (HCC) dominated the liver cancer drug market with a 36.6% revenue share in 2023. HCC Is the most common type of primary liver cancer.

• Hospital pharmacy dominated the liver cancer drug market with a revenue share of 45.5% in 2023.

• North America liver cancer drug market held a revenue share of 42.7% in 2023.

Liver Cancer Drug Market Segmentation

Grand View Research has segmented the global liver cancer drug market on the basis of drug, type, distribution channel and region:

Liver Cancer Drug Outlook (Revenue, USD Million, 2018 - 2030)

• Targeted Therapy

• Immunotherapy

• Chemotherapy

Liver Cancer Drug Type Outlook (Revenue, USD Million, 2018 - 2030)

• Hepatocellular Carcinoma

• Cholangio Carcinoma

• Hepatoblastoma

• Others

Liver Cancer Drug Distribution Chanel Outlook (Revenue, USD Million, 2018 – 2030)

• Hospital Pharmacy

• Retail Pharmacy

• Online Pharmacy

Liver Cancer Drug Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa (MEA)

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players of Liver Cancer Drug Market

• Exelixis, Inc.

• Merck KGaA

• Eisai Co., Ltd.

• Bristol-Myers Squibb Company

• Bayer AG

• Thermo Fisher Scientific Inc.

• Pfizer Inc.

• Eli Lilly and Company

• F. Hoffmann-La Roche Ltd

• Novartis AG

• Bayer AG